Ascentage Pharma Presents Lisaftoclax Data at ASH Meeting
Ticker: AAPG · Form: 6-K · Filed: Dec 8, 2025 · CIK: 2023311
Sentiment: neutral
Topics: clinical-trial-data, conference-presentation, press-release
TL;DR
Ascentage Pharma dropped ASH meeting data for Lisaftoclax on Dec 6th.
AI Summary
Ascentage Pharma Group International announced on December 6, 2025, that it presented pivotal China registrational study data for its drug Lisaftoclax at the 2025 American Society of Hematology (ASH) Annual Meeting. This presentation was detailed in a press release furnished as Exhibit 99.1 to their 6-K filing.
Why It Matters
The presentation of study data for Lisaftoclax at a major hematology conference could impact the drug's development and potential market approval, affecting patient access and the company's future revenue.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain new financial or operational information that would significantly alter risk perception.
Key Players & Entities
- Ascentage Pharma Group International (company) — Registrant
- Lisaftoclax (drug) — Drug being studied
- December 6, 2025 (date) — Date of press release
- 2025 American Society of Hematology (ASH) Annual Meeting (event) — Conference where data was presented
FAQ
What specific data was presented for Lisaftoclax at the ASH meeting?
The filing states that pivotal China registrational study data for Lisaftoclax was presented, but does not provide specific details of the data itself.
When was the press release regarding the ASH presentation issued?
The press release was issued on December 6, 2025.
What is the primary purpose of this 6-K filing?
The primary purpose is to report a press release issued by Ascentage Pharma Group International regarding study data presented at the 2025 ASH Annual Meeting.
Where is Ascentage Pharma Group International's principal executive office located?
Ascentage Pharma Group International's principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Does Ascentage Pharma Group International file annual reports under Form 20-F or 40-F?
Ascentage Pharma Group International files annual reports under cover of Form 20-F.
Filing Stats: 266 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2025-12-08 08:00:21
Filing Documents
- ea0268770-6k_ascent.htm (6-K) — 12KB
- ea026877001ex99-1_ascent.htm (EX-99.1) — 33KB
- ea026877001ex99-2_ascent.htm (EX-99.2) — 28KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- ex99-2_001.jpg (GRAPHIC) — 10KB
- 0001213900-25-118963.txt ( ) — 102KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On December 6, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting”. A copy of the press release is furnished as Exhibit 99.1 to this Report. On December 8, 2025, Ascentage Pharma Group International issued a press release entitled “ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances”. A copy fo the press release is furnished as Exhibit 99.2 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated December 6, 2025 99.2 Press Release dated December 8, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: December 8, 2025 /s/ Dajun Yang Name: D ajun Yang Title: Chief Executive Officer 3